What Semaglutide Did for People

What changed in the biggest human studies

Semaglutide has FDA approval for type 2 diabetes and lasting weight control. It can also lower heart risk for some people with obesity. In 2025, approval grew to one liver disease in which fat causes swelling and scars.

The medicine acts like GLP-1, a hormone your gut releases after food. That hormone helps you feel full, release insulin, and move food through your stomach more slowly. This GLP-1 medicine lasts about one week.

One 17,604-person heart study followed adults ^[3]. A 3,533-person kidney study followed adults ^[2]. Another test put semaglutide beside tirzepatide ^[1]. BPC-157 has no study near that size. At your visit, ask whether the people studied had heart, kidney, liver, and eye problems like yours. You’ll want the answer tied to your own health.

Why one treatment can last about a week

Semaglutide joins 31-amino-acid parts, the small pieces that make protein. Its shape is about 94% like GLP-1, the gut hormone it follows. The paper numbers parts 8 and 34, but those places don’t predict whether you’ll benefit. The number 4 belongs to an old lab name and tells you nothing about benefit.

The paper also points to part 26. That detail concerns how long the medicine stays in blood, not how much weight you may lose. Your kidneys clear semaglutide slowly, so its effect lasts about one week. The medicine comes as a shot under the skin or a pill. Your body absorbs very little from the pill. You can ask which form was used in the study that matters to you.

How hunger and blood sugar may change

Semaglutide acts like GLP-1, a gut hormone that affects your pancreas, stomach, and brain. When sugar rises in your blood, the medicine helps your pancreas release insulin. Food leaves your stomach more slowly. Those changes may improve blood sugar and help you feel full.

In rats, semaglutide reached parts of the brain involved in hunger. The rats ate less, while their calorie use stayed about the same ^[6]. Some people say thoughts about food become quieter. One person’s account can’t predict your response. Ask what change would show the medicine is helping you. If it isn’t, ask what happens at the next visit. That’s a useful question for your next visit.

What five large studies found in people

Five large human studies give the firmest answers.

Weight. A study named STEP 1 followed 1,961 adults with excess weight for 68 weeks. Those taking semaglutide lost more than people given placebo, a shot with no medicine ^[4].

Against tirzepatide. A study named SURMOUNT-5 followed 751 adults with obesity. At 72 weeks, people on tirzepatide had lost more weight ^[1].

Heart trouble. The study included 17,604 adults who already had heart disease. Semaglutide cut the joined risk of heart death, heart attack, or stroke by 20% compared with placebo ^[3]. Researchers used a 95% check to ask whether chance could explain the drop. Their check said chance was unlikely.

Kidney trouble. A study enrolled 3,533 people with type 2 diabetes and long-term kidney disease. The main kidney risk fell by 24%. That meant fewer cases of kidney failure, a loss of at least 50% of kidney work, or death tied to the heart or kidneys ^[2]. A 95% check again said chance was unlikely.

Eye trouble from type 2 diabetes. A study named SUSTAIN-6 included 3,297 people with high heart risk. Serious diabetic eye trouble occurred more often with semaglutide. A 95% check supported the heart benefit. Another 95% check said the added eye trouble may be real. Most cases were in people with prior eye disease whose blood sugar fell fast ^[7]. You can ask which result matters most for you.

What people feel and which signs need a call

They're personal accounts from people taking semaglutide. No study assigned care and counted these accounts as a group: Some people say hunger and thoughts of food ease within a week or two. Others lose interest in sweet food, rich meals, or alcohol. People also report nausea, rotten-egg burps, constipation, diarrhea, tiredness, and heartburn. Trouble may peak after an increase, then ease within a week or two. Some mention hair loss or a thinner face after fast weight loss. These accounts can’t show how often a change occurs.

Studies and the medicine label list these risks:

• Stomach and bowel trouble: When several study results were joined, about one-third of people had nausea. It often passed fast, yet it was the main reason people stopped ^[5].
• Thyroid tumors: The FDA puts its strongest label warning, called a boxed warning, on this risk because rats developed tumors. A rare inherited gland problem called MEN-2, or certain thyroid cancers in you or your family, may rule out the drug. Human studies haven’t shown a clear cancer link ^[5].
• Eye disease from diabetes: SUSTAIN-6 found more eye trouble when blood sugar fell fast in people who already had eye disease ^[7]. Ask how your eyes would be checked and which changes require a call.
• Gallstones: Gallstones occurred more often than with placebo, perhaps because weight fell fast ^[5].
• Muscle loss: Part of the weight people lost came from muscle, rather than fat. Muscle matters more with age because it helps you stay strong and steady.
• Weight after stopping: In STEP 1 and STEP 4, much of the lost weight returned after people stopped.
• Pregnancy: The medicine isn’t used during pregnancy. Its label calls for about two months between stopping and trying to become pregnant.
• Pharmacy-made semaglutide: During the shortage, some copies led to dose errors and hospital stays. Once the shortage ended in 2025, the FDA stopped most pharmacies from making those copies ^[5]. You’ll know whom to call if trouble starts.

Questions to ask before the visit ends

Semaglutide has a 17,000-patient heart study and a direct test against tirzepatide ^[3][1]. That proof is much firmer than animal work or a test with two people.

Ask, “What health change are we trying to make for me?” Then ask how long care may last, what it may cost, and which side effects call for help. Tirzepatide is approved but newer. Tesamorelin has one narrow approval. Retatrutide has only Phase 2, an earlier human round, while BPC-157 lacks approval ^[23].

I’d bring the five-compound comparison to keep those gaps clear. Write down the answers while you’re there.